Palivizumab vs Motavizumab: Incidence of RSV Hospitalization (Includes Deaths by RSV)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0188 | 0.0147 | 0.024 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0138 | 0.0104 | 0.0184 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00494 | -0.0012 | 0.0112 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.36 | 0.93 | 1.98 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.36 | 0.929 | 2 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Palivizumab than on Motavizumab | 203 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Palivizumab | Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses | 62 | 3,306 | OG000 | ClinicalTrials.gov |
| Group 2 | Motavizumab | Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses | 46 | 3,329 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Incidence of RSV Hospitalization (Includes Deaths by RSV) | ClinicalTrials.gov |
| Description | RSV hospitalization was defined as 1) a respiratory hospitalization with a positive RSV test (primary), 2) a new onset of lower respiratory symptoms in an already hospitalized child, with an objective measure of worsening respiratory status and positive RSV test (nosocomial), or 3) death demonstrated to have been caused by RSV (by autopsy or clinical history and virologic evidence). | ClinicalTrials.gov |
| Time frame | Days 0 - 150 | ClinicalTrials.gov |
| Population | The Intent-to-Treat (ITT) Population included all patients randomized into the study. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children | ClinicalTrials.gov |
| NCT number | NCT00129766 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Respiratory Syncytial Virus Infections | ClinicalTrials.gov |
| Interventions | motavizumab (MEDI-524), palivizumab | ClinicalTrials.gov |
| Lead sponsor | MedImmune LLC | ClinicalTrials.gov |
| Results first posted | 2013-08-28 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00129766?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.